ArticleJournal of translational medicine2025
Conserved sphingolipid metabolism under transcriptomic diversity: a prognostic and therapeutic target in triple-negative breast cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) exhibits significant transcriptomic diversity, limiting treatment efficacy. This study aims to identify conserved molecular pathways that remain stable in heterogeneous TNBC, providing reliable therapeutic and prognostic targets.
methodsGenomic diversity was assessed via Mutant-Allele Tumor Heterogeneity (MATH) in TCGA-TNBC cohorts. Single-cell RNA sequencing from TNBC samples (GSE176078) underwent non-negative matrix factorization (NMF) to identify intratumoral heterogeneity (ITH) metaprograms. Transcriptomic diversity was quantified using PCA-based cell-cell Euclidean distances. CellChat analyzed cellular communication in high- and low-diversity groups. Conserved pathways were identified using KEGG enrichment, ssGSEA, and spatial transcriptomics. And we confirmed the feasibility of targeting sphingolipid metabolism through in vitro and in vivo experiments.
resultsTNBC showed elevated genomic diversity, inversely correlated with immune infiltration and pathway activity. Single-cell RNA sequencing revealed ITH metaprograms across malignant subtypes, with Cancer Cycling cells showing proliferative enrichment. High transcriptomic diversity tumors exhibited enhanced Cancer Basal SC interactions with CAFs, promoting stemness and EMT. Multi-region TNBC dataset analysis confirmed sphingolipid metabolism as the most conserved pathway (high interpatient and low intratumoral heterogeneity), enriched in malignant regions and negatively correlated with immune cells. A prognostic model incorporating sphingolipid genes (SPTLC2, SGMS1, SGPP2) stratified high-risk patients. Inhibiting SPHK1 via PF-543 induced dose-dependent cell death.
conclusionSphingolipid metabolism could be a transcriptionally conserved pathway in TNBC. Its inhibition may overcome heterogeneity-driven resistance, and its prognostic value enables precise patient stratification, offering a potential strategy against TNBC plasticity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.